PE20091089A1 - PHARMACEUTICAL COMPOSITIONS INCLUDING 4 - [(4-CHLOROPHENYL) METHYL] -2 - ({(2R) -1- [4- (4 {[3- (HEXAHYDRO-1H-AZEPIN-1-IL) PROPYL] OXY} PHENYL ) BUTYL] -2-PYRROLIDINYL} METHYL) -1 (2H) -PHTHALAZINONE AND FLUTICASONE FUROATE - Google Patents
PHARMACEUTICAL COMPOSITIONS INCLUDING 4 - [(4-CHLOROPHENYL) METHYL] -2 - ({(2R) -1- [4- (4 {[3- (HEXAHYDRO-1H-AZEPIN-1-IL) PROPYL] OXY} PHENYL ) BUTYL] -2-PYRROLIDINYL} METHYL) -1 (2H) -PHTHALAZINONE AND FLUTICASONE FUROATEInfo
- Publication number
- PE20091089A1 PE20091089A1 PE2008001765A PE2008001765A PE20091089A1 PE 20091089 A1 PE20091089 A1 PE 20091089A1 PE 2008001765 A PE2008001765 A PE 2008001765A PE 2008001765 A PE2008001765 A PE 2008001765A PE 20091089 A1 PE20091089 A1 PE 20091089A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- methyl
- total weight
- amount
- oxy
- Prior art date
Links
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 title abstract 2
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001469 fluticasone furoate Drugs 0.000 title abstract 2
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- -1 2-FURANYLCARBONYL Chemical class 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229940069338 potassium sorbate Drugs 0.000 abstract 1
- 235000010241 potassium sorbate Nutrition 0.000 abstract 1
- 239000004302 potassium sorbate Substances 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
- 239000000811 xylitol Substances 0.000 abstract 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 1
- 229960002675 xylitol Drugs 0.000 abstract 1
- 235000010447 xylitol Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA ACUOSA QUE COMPRENDE: A) 4-[(4-CLOROFENIL)METIL]-2-({(2R)-1-[4-(4{[3-(HEXAHIDRO-1H-AZEPIN-1-IL)PROPIL]OXI}FENIL)BUTIL]-2-PIRROLIDINIL}METIL)-1(2H)-FTALAZINONA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.005% a 2% (p/p) DEL PESO TOTAL DE LA COMPOSICION Y B) UN COMPUESTO QUE ES ESTER S-FLUOROMETILICO DE ACIDO 6ALFA,9ALFA-DIFLUORO-17ALFA-[(2-FURANILCARBONIL)OXI]-11BETA-HIDROXI-16ALFA-METIL-3-OXO-ANDROSTA-1,4-DIEN-17BETA-CARBOTIOICO (FUROATO DE FLUTICASONA) EN UNA CANTIDAD DE 0.01% a 1% (p/p) DEL PESO TOTAL DE LA COMPOSICION, DONDE ADEMAS, PUEDE CONTENER UN AGENTE SUSPENSOR TAL COMO CELULOSA MICROCRISTALINA O CARBOXIMETILCELULOSA EN UNA CANTIDAD DE 1,5% A 2,4% (p/p) DEL PESO TOTAL DE LA COMPOSICION, UN AGENTE DE CONSERVACION TAL COMO ETILENDIAMONOTETRAACETATO SODICO (EDTA) O SORBATO POTASICO EN UNA CANTIDAD DE 0.001% A 1% (p/p) DEL PESO TOTAL DE LA COMPOSICION, UN AGENTE HUMECTANTE TAL COMO MONOOLEATO DE SORBITAN POLIOXIETILENO EN UNA CANTIDAD DE 0.01% A 0.05% (p/p) DEL PESO TOTAL DE LA COMPOSICION, UN AGENTE REGULADOR DE ISOTONICIDAD TAL COMO DEXTROSA O XILITOL EN UNA CANTIDAD DE 0.1% A 10% (p/p) DEL PESO TOTAL DE LA COMPOSICION Y UN CO-DISOLVENTE TAL COMO PROPILENGLICOL EN UNA CANTIDAD DE 1,5% A 17,5% (p/p) DEL PESO TOTAL DE LA COMPOSICION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO ENFERMEDADES INFLAMATORIAS O ALERGICAS TALES COMO RINITIS ALERGICAREFERRING TO AN AQUEOUS PHARMACEUTICAL COMPOSITION INCLUDING: A) 4 - [(4-CHLOROPHENYL) METHYL] -2 - ({(2R) -1- [4- (4 {[3- (HEXAHYDRO-1H-AZEPIN-1- IL) PROPYL] OXY} PHENYL) BUTYL] -2-PYRROLIDINYL} METHYL) -1 (2H) -PHTHALAZINONE WHICH IS IN A QUANTITY OF 0.005% to 2% (w / w) OF THE TOTAL WEIGHT OF THE COMPOSITION AND B) A S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALFA-DIFLUORO-17ALPHA - [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTA-1,4-DIEN-17BETA-CARBOTHYL ACID COMPOUND THAT IS FLUTICASONE FUROATE) IN A QUANTITY OF 0.01% to 1% (p / p) OF THE TOTAL WEIGHT OF THE COMPOSITION, WHERE IN ADDITION, IT MAY CONTAIN A SUSPENDING AGENT SUCH AS MICROCRYSTALLINE CELLULOSE OR CARBOXIMETHYL CELLULOSE IN AN AMOUNT OF 1.5% TO 2 4% (w / p) OF THE TOTAL WEIGHT OF THE COMPOSITION, A PRESERVATION AGENT SUCH AS ETHYLENEDIAMONOTETRAACETATE SODIUM (EDTA) OR POTASSIUM SORBATE IN AN AMOUNT OF 0.001% TO 1% (w / p) OF THE TOTAL WEIGHT OF THE COMPOSITION, A WETTING AGENT SUCH AS SORBITAN POLYOXYETHYLENE MONOOLEATE IN AN AMOUNT OF 0.01% TO 0 .05% (p / p) OF THE TOTAL WEIGHT OF THE COMPOSITION, AN ISOTONICITY REGULATOR AGENT SUCH AS DEXTROSE OR XYLITOL IN AN AMOUNT OF 0.1% TO 10% (p / p) OF THE TOTAL WEIGHT OF THE COMPOSITION AND A CO-SOLVENT SUCH AS PROPYLENE GLYCOL IN AN AMOUNT OF 1.5% TO 17.5% (p / p) OF THE TOTAL WEIGHT OF THE COMPOSITION. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC DISEASES SUCH AS ALLERGIC RHINITIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98022607P | 2007-10-16 | 2007-10-16 | |
| US5723008P | 2008-05-30 | 2008-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091089A1 true PE20091089A1 (en) | 2009-08-24 |
Family
ID=40198721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001765A PE20091089A1 (en) | 2007-10-16 | 2008-10-14 | PHARMACEUTICAL COMPOSITIONS INCLUDING 4 - [(4-CHLOROPHENYL) METHYL] -2 - ({(2R) -1- [4- (4 {[3- (HEXAHYDRO-1H-AZEPIN-1-IL) PROPYL] OXY} PHENYL ) BUTYL] -2-PYRROLIDINYL} METHYL) -1 (2H) -PHTHALAZINONE AND FLUTICASONE FUROATE |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR068988A1 (en) |
| CL (1) | CL2008003036A1 (en) |
| PE (1) | PE20091089A1 (en) |
| TW (1) | TW200932243A (en) |
| UY (1) | UY31400A1 (en) |
| WO (1) | WO2009050159A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0811447D0 (en) * | 2008-06-20 | 2008-07-30 | Glaxo Group Ltd | Formulations |
| RU2652352C2 (en) * | 2012-12-17 | 2018-04-25 | Глаксо Груп Лимитед | Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| US20090105225A1 (en) * | 2006-04-20 | 2009-04-23 | Glaxo Group Limited | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists |
-
2008
- 2008-10-14 PE PE2008001765A patent/PE20091089A1/en not_active Application Discontinuation
- 2008-10-14 CL CL2008003036A patent/CL2008003036A1/en unknown
- 2008-10-14 AR ARP080104473A patent/AR068988A1/en not_active Application Discontinuation
- 2008-10-14 TW TW097139419A patent/TW200932243A/en unknown
- 2008-10-14 WO PCT/EP2008/063781 patent/WO2009050159A1/en not_active Ceased
- 2008-10-16 UY UY31400A patent/UY31400A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009050159A1 (en) | 2009-04-23 |
| TW200932243A (en) | 2009-08-01 |
| AR068988A1 (en) | 2009-12-23 |
| UY31400A1 (en) | 2009-05-29 |
| CL2008003036A1 (en) | 2009-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090948A1 (en) | 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR (FLAP) | |
| PE20060427A1 (en) | PIRAZOLE DERIVATIVES AS GLUCAGON BINDING INHIBITORS AND COMPOSITIONS | |
| AR051592A1 (en) | MICRONIZED FORMULATIONS TO CONSERVE WOOD | |
| ES2721148T3 (en) | Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use | |
| ATE488499T1 (en) | PHENOXYPYRROLIDINE DERIVATIVE, ITS USE AND COMPOSITIONS THEREOF | |
| PE20091011A1 (en) | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS, WITHOUT ALCOHOL | |
| EP1089715A4 (en) | AQUEOUS COMPOSITIONS CONTAINING THE CORTICOSTEROIDS FOR NASAL OR PULMONAL ADMINISTRATION | |
| GT200800058A (en) | DIARILURE FOR THE TREATMENT OF PULMONARY HYPERTENSION | |
| PE20081365A1 (en) | TOPICAL FORMULATIONS FOR LOCAL ADMINISTRATION CONTAINING INDOXACARB | |
| UY29575A1 (en) | POLYMODIC FORMS OF ETHYL ETHYL ESTER 3 - ((2 - ((4- (HEXILOXICARBONILAMINO - IMINO-METIL) -PENYLAMINO) -METIL) -1-METHYL-BENCIMIDAZOL-5-CARBONIL) -PIRIDIN-2-IL - -AMINO) -PROPIÓNICO | |
| PE20100265A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS INCLUDING LEVETIRACETAM AND PROCESS FOR ITS PREPARATION | |
| PE20120023A1 (en) | PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST ONE SURFACE-ACTIVE SUBSTANCE | |
| WO2009028495A1 (en) | Agent for fungal dermatitis | |
| EA201070698A1 (en) | SOLID FORMS OF 3- (6- (1- (2,2-DIFTLOROXENO [D] [1,3] -DIOXOL-5-IL) CYCLOPROPANKARAROXAMIDO) -3-METHYLPYRIDIN-2-IL) Benzoic Acid | |
| MA33836B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING LIGANDS OF SIGMA RECEPTORS | |
| PE20140572A1 (en) | DRUG COMBINATIONS INCLUDING A DGAT INHIBITOR AND A PPAR AGONIST | |
| PE20060736A1 (en) | DERIVATIVES OF PIRROL AS ANTAGONISTS OF CRTh2 | |
| NO20090407L (en) | Aerosol formulation for inhalation of beta agonists | |
| PE20070437A1 (en) | AQUEOUS FORMULATION hFSH | |
| PE20071231A1 (en) | PHARMACEUTICAL FORMULATIONS OF PLECONARIL | |
| PE20091032A1 (en) | COMPOSITION CONTAINING N- (3-METHOXY-5-METHYLPYRAZIN-2-IL) -2- (4- [1,3,4-OXADIAZOL-2-IL] PHENYL) PYRIDIN-3-SULFONAMIDE (ZIBOTENTAN) | |
| PE20091089A1 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING 4 - [(4-CHLOROPHENYL) METHYL] -2 - ({(2R) -1- [4- (4 {[3- (HEXAHYDRO-1H-AZEPIN-1-IL) PROPYL] OXY} PHENYL ) BUTYL] -2-PYRROLIDINYL} METHYL) -1 (2H) -PHTHALAZINONE AND FLUTICASONE FUROATE | |
| NO20063810L (en) | Hydroisoindolintakykininreseptorantagonister | |
| PE20110844A1 (en) | SOLID PHARMACEUTICAL COMPOSITION | |
| AR054118A1 (en) | PIRAZOLCARBOXILICO ACID AMIDAS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |